GLS and renal cell carcinoma: Indeed, while inhibition of GLS1 reduces aspartate production and the proliferation of von Hippel–Lindau (VHL)−/− renal cell carcinoma (RCC) cells, VHL+/+ cells can adapt by increasing glucose contribution to the TCA cycle and aspartate biosynthesis [12].